Algernon Pharmaceuticals Inc.

DB:AGW0 Stock Report

Market Cap: €1.0m

Algernon Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:AGW0 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Nov 24Buy€808Christopher MoreauIndividual15,000€0.054
07 Oct 24Buy€536Christopher MoreauIndividual10,000€0.054
20 Sep 24Buy€1,189James KinleyIndividual20,000€0.059
01 Aug 24Buy€33,992Christopher MoreauIndividual423,000€0.08
01 Aug 24Buy€18,081James KinleyIndividual225,000€0.08
27 Jun 24Buy€1,463Christopher MoreauIndividual19,500€0.075
20 Jun 24Buy€368Christopher MoreauIndividual4,500€0.082
05 Jun 24Buy€1,365Christopher MoreauIndividual14,500€0.094
17 May 24Buy€1,940Christopher BryanIndividual20,500€0.095
17 May 24Buy€2,931Christopher MoreauIndividual30,000€0.098
16 May 24Buy€1,056James KinleyIndividual12,500€0.084
10 May 24Buy€3,192Christopher BryanIndividual40,000€0.082
26 Apr 24Buy€3,380Christopher MoreauIndividual38,000€0.089

Insider Trading Volume

Insider Buying: AGW0 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AGW0?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,340,56615.7%
Institutions4,550,88021.4%
General Public13,409,73363%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.

Top Shareholders

Top 8 shareholders own 37.05% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
21.1%
AlphaNorth Asset Management
4,502,880€212.1k0%5.01%
7.3%
Christopher Moreau
1,556,002€73.3k1.63%no data
5.02%
James Kinley
1,068,492€50.3k29.8%no data
1.8%
Harold J. Bloomfield
383,332€18.1k0%no data
0.81%
Howard Gutman
173,180€8.2k0%no data
0.54%
Rajpaul Attariwala
114,760€5.4k0%no data
0.23%
Eldee Foundation, Endowment Arm
48,000€2.3k0%100.0%
0.21%
Mark Williams
44,800€2.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 00:18
End of Day Share Price 2025/01/07 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Algernon Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andre UddinResearch Capital Corporation